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Quetiapine FumarateAbstract The problem of inadequate oral bioavailability of Quetiapine Fumarate, a lipophilic
drug used for schizophrenia, due to hepatic metabolism and repulsion by brain barrier was
attempted in this study. Combination of two approaches, viz. Quetiapine inclusion into the liposo-
mal carrier for better diffusion and administration through nasal route to avoid hepatic metabolism
and barrier elimination was applied. Thin film hydration followed by sonication method was
employed in liposome preparation and the formulation was optimized using 32 full factorial design.
The number of sonication cycles (X1) of 2 min and 80% amplitude and molar ratio of construc-
tional components such as cholesterol to egg phosphatidylcholine (X2) as independent variables
and a % of entrapment efficiency (Y1) and cumulative in vitro drug release (Y2) at 6 h as dependent
variables was selected. Batch F7 prepared by 2 cycles of sonication and 1:3 M ratio of cholesterol:
egg phosphatidylcholine was optimized as a consequence of substantial entrapment efficiency of
75.63 ± 3.77%, and 99.92 ± 1.88% drug release and 32.33 ± 1.53% drug diffusion, which was
optimum among all other batches at 6 h. Diffusion study was done for all the batches of liposomal
formulation by using sheep nasal mucosa and good amount with better diffusion rate was measured
which proved liposomal dispersion a virtuous delivery system for brain drug delivery through nasal
route. Results of in vivo, ciliotoxicity and gamma scintigraphy studies on mice supported the above
inference.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).tors and
al route.
2 P. Upadhyay et al.1. Introduction
Schizophrenia is a disorder of brain and characterized by the
sudden breakdown of thought processes and by poor emo-
tional responses. In contrast to other tissues, brain endothelial
cells are more intimately associated and that prevent access of
any potentially toxic substances into the brain (Pardridge,
1999). Any molecule enters through the blood into the brain
is restricted by this barrier made up of endothelial cells’ ‘‘Tight
Junctions” or ‘‘Zonula Occludens” or also called as blood brain
barrier (BBB) (Misra et al., 2003). Owing to its stringent pen-
etrability, it is presumed to be the key obstacle in the develop-
ment of central nervous system (CNS) targeted drug delivery
(Pathan et al., 2009). Various strategies to use different routes
of drug administration than oral or parenteral route such as
intranasal and olfactory route and like to use drug nanocarri-
ers have been applied to cope with the problem of the trans-
portation across the blood brain barrier (Abbott and
Romero, 1996).
The historical backdrop of nasal drug transportation goes
once again to prior topical applications of medications pro-
posed for local effects (Alsarra et al., 2010). Intranasal drug
delivery has numerous focal compensation over other routes
of drug administration (Behl et al., 1998; Costantino et al.,
2007; Illum, 2000). Late improvements in nasal drug delivery
have recommended intranasal administration as a safe and
adequate course for brain targeting, especially for drugs with
biological consequences on the CNS and constrained BBB per-
meability (Watts et al., 2002). The Olfactory region is of signif-
icant interest toward medication conveyance in light of the fact
that it evades the BBB, conveying restorative drugs to the CNS
(Frey, 2002). Nasal delivery is easily accessible, convenient,
and a dependable system, with a porous endothelial mem-
brane, and a profoundly vascularized epithelium that provides
a quick assimilation of the compound into the systemic circu-
lation, circumventing the hepatic first pass disposal (Parmar
et al., 2011; Tu¨rker et al., 2004). In addition to that, intranasal
drug delivery enables reduction in the dose, quick therapeutic
level attainment of the drug into the blood, speedier onset of
pharmacological activity, and fewer side effects (Arora et al.,
2002; Ugwoke et al., 2001). It is reported that lipophilic drugs
are by and large, well absorbed from the nasal cavity with
pharmacokinetic profiles, which are frequently indistinguish-
able to those acquired after an intravenous infusion with a
bioavailability approaching 100% (Aacharya et al., 2015).
Strategy of delivering the drug by intranasal route could be
effective in the delivery of therapeutic proteins such as brain
delivered neurotropic factor (BDNF) to the olfactory bulb as
a treatment for Alzheimer’s disease (Thorne et al., 1995).
Colloidal drug transporters resembling micelles, emulsions,
liposomes and nanoparticles have been largely accounted for
brain drug delivery because methods of preparation are gener-
ally simple and easy to scale-up (Garcia et al., 2005; Woensel
et al., 2013). Liposomes are self-assembling colloidal structures
comprising of lipid bilayers encompassing an aqueous com-
partment, and can typify the wide range of hydrophilic drugs
within this compartment (Pathan et al., 2009). Liposomes have
been demonstrated to provide stable epitome to different drugs
and offer unique focal points over un-encapsulated agents
(Lasic and Papahadjopoulos, 1995).Please cite this article in press as: Upadhyay, P. et al., Direct and enhanced delivery
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assortment of applications in research, industry, and medicine,
especially for the utilization as transporters of symptomatic
and therapeutic compounds (Fang et al., 2009). The unique
ability of liposomes to entrap drugs, in both an aqueous and
a lipid phase makes such delivery systems attractive for
hydrophobic and hydrophilic drugs, such encapsulation
proved to reduce drug toxicity while retaining or improving
the therapeutic adequacy (Fielding, 1991). Liposomes are most
commonly used carrier of mixes for brain delivery in vivo
(Afergan et al., 2008; Schnyder et al., 2005; Shi et al., 2001;
Xie et al., 2005) and proved to enhance bioavailability of
numerous deprived agents into the brain (Alsarra et al.,
2008; Arumugam et al., 2008; Hamed et al., 2012; Vyas
et al., 1995).
Quetiapine Fumarate (QTF) is indicated for the treatment
of schizophrenia and also for the acute manic episodes associ-
ated with bipolar I disorder. QTF is an antipsychotic drug with
limited oral bioavailability (7–9%) due to hepatic metabolism
and excision by the blood brain barrier (Brayfield and
Sweetman, 2007). Albeit numerous endeavors have been made
to attain brain entry of QTF, it doesn’t efficiently infiltrate into
the BBB (Kararli et al., 1992; Lohan et al., 2015).
It was hypothesized that if saline liposomal suspension of
QTF administered through nasal route, it would avoid hepatic
first pass metabolism and BBB crossover, and hence could
achieve improved bioavailability and brain targeted drug deliv-
ery. The objective of the present study was to formulate differ-
ent factorial batches of QTF liposomes by varying the molar
ratio of constructional components and optimize by compar-
ison for % entrapment efficiency and % drug release with
time. The applied factorial design was validated and all the
batches were further evaluated for diffusion through the sheep
nasal mucosa by ex vivo. The optimized batch was then radio-
labeled and compared with the simple solution of 99mTc in sim-
ulated nasal fluid (SNF) using a gamma scintigraphy study,
which is then sustained by comparison of liposomal dispersion
with the simple dispersion of QTF by in vivo study in mice.
2. Materials and method
2.1. Materials
QTF was a generous gift from Elite pharmaceuticals, Ahmed-
abad. Egg Phosphatidylcholine (EPC) was obtained as a gift
sample from Vav Life sciences Pvt. Ltd., Mumbai, and Choles-
terol (CH) was purchased from Astron Chemicals,
Ahmedabad.
2.2. Analytical method
QTF is analyzed for %EE, %CDR and % diffusion study by
Uv double beam spectrophotometer (Shimadzu-1800, Japan)
in SNF, pH 6.8 by generating standard curve for the entire
range from 5 to 25 lg/ml at 242 nm (Sahu and Rana, 2011;
Vincenzo et al., 2003). The method used for estimation of
QTF in brain homogenate and plasma involves high perfor-
mance liquid chromatography (HPLC) analysis (Model LC)
using a C18 column with Uv detector. Mobile phase consists
of phosphate buffer (pH 3): Acetonitrile: Methanolof nanoliposomes of anti schizophrenic agent to the brain through nasal route.
Table 1 Formulation design with coded values.
CH:EPC (X2) Sonication cycles (2 min. 80%
amp.) (X1)
Batch
Coded value Molar ratio Coded value Cycles
1 1:1 1 2 F1
0 3 F2
+1 4 F3
0 1:2 1 2 F4
0 3 F5
+1 4 F6
+1 1:3 1 2 F7
0 3 F8
+1 4 F9
Nanoliposomal Quetiapine Fumarate delivery to the brain through nasal route 3(50:40:10) and flow rate were 0.8 ml/min. The sample volume
injected is 20 ll and wavelength was 247 nm (Reddy et al.,
2011).
2.3. Preparation of liposomes
Liposomes of QTF were prepared by modifying thin lipid film
hydration technique using a rotary flask evaporator as
described by the method of Bangham, Juliano and Daoud
(Senthilkumar et al., 2012). Process parameters such as solvent
system, rehydration volume, vacuum, drying and hydration
time, temperature and flask rotation speed were optimized
on the basis of morphology of the film formed and particle size
distribution by preliminary screening. These all the factors
were analyzed for their effects on the blank liposome forma-
tion. The effect of one variable was studied at a time, keeping
other variables constant. Amount of drug was screened at last
(Rathod and Deshpande, 2010; Shariat et al., 2014).
In the first step of the preparation, CH: EPC in the different
molar ratio and 38.35 mg of QTF (molar ratio of 1) was dis-
solved in 10 ml of methanol: chloroform solution of 2:1 ratio.
The flask was attached to the rotary evaporator and rotated at
90 rpm speed for 120 min at 37 C temperature (Tm of EPC)
under vacuum (600 mmHg). Our preliminary study findings
showed that liposome size, zeta potential and drug leaching
are lowered at reduced temperature, which reflects in more per-
centage liposomal yield and higher drug entrapment while dry-
ing time is oppositely increased. The organic solvent was
slowly removed by this process such that a very thin, smooth
and dry film of lipid was formed on the inner surface of the
flask. The film was allowed to dry for 1 h under vacuum and
temperature previously mentioned. The dry lipid film was then
slowly hydrated with an aqueous phase (10 ml SNF, pH 6.8)
and the flask was again rotated at the same speed for 30 min
at 37 C. Liposomal dispersion was left to mature overnight
just below 20 C to ensure full lipid hydration. The liposomal
dispersion obtained was filled in glass ampoules and sonicated
for 2 min at 80% amplitude and then was subjected to cen-
trifugation at 5000 rpm, 8 C for 5 min using Remi ultracen-
trifuge. Liposomal suspension was separated from drug and
debris pellet and stored in refrigerator (Liu et al., 2013).
Here, the drug is water insoluble so it will not be in a molec-
ular state and free drug will separate at lower rpm. Similarly,
insoluble fragments and crystals of cholesterol and the EPC
will settle down in form of pellets. The number of sonication
cycles was varied from 2 to 4 times. The time was fixed for only
2 min as above that liposomal dispersion starts getting heat
and drug leaches out which results into deprived entrapment
efficiency. The amplitude of sonication was kept 80% as it
increases sonochemical effect which results in the fine particle
formation (Santos and Lodeiro, 2009).
2.4. Experimental design
A 32 full factorial design was utilized in the present study
(Ghanbarzadeh et al., 2013). Several studies revealed that the
ratio of CH: EPC plays notable role in lamellar configuration
and sonication plays important role in structure type of the
Liposomes (Nill, 2003; Joseph and Zasadzinski, 1986). These
both effects fall out significant impact on entrapment of the
drug and release of the drug from liposomal lamellaPlease cite this article in press as: Upadhyay, P. et al., Direct and enhanced delivery
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two factors were evaluated, each at three levels, and experi-
mental trials were carried out at all nine possible combina-
tions. The design layouts and coded value of independent
factor are shown in Table 1. The molar ratio of CH: EPC
and the number of sonication cycles of 2 min and 80% ampli-
tude were selected as independent variables. The % entrap-
ment efficiency and % cumulative drug release (%CDR) of
QTF were selected as dependent variables.
2.5. Characterization and evaluation
2.5.1. Drug - excipient compatibility study
The compatibility study was carried out by using Fourier
transform infrared spectroscopy (FTIR) (MIRacle-10, Shi-
madzu, Japan) (Pavia et al., 2008). The physical mixtures of
1:1 were prepared for QTF and egg lecithin, drug and physical
mixture (cholesterol and egg lecithin) and also for egg lecithin
and individual dry ingredients of the simulated nasal fluid that
is potassium chloride (KCl), sodium chloride (NaCl) and cal-
cium chloride (CaCl2). These mixtures were kept for one
month at room temperature that is 25 C± 2 C and 60%
± 5% relative humidity for complete interaction between the
drug and polymer. The drug and drug-polymer samples were
dried in hot air oven at 60 C for 30 min for removal of mois-
ture. These samples were scanned from 4000 to 400 cm1 wave
numbers. Spectra obtained were compared with spectra of
QTF sample for changes in the peaks if any interaction
transpires.
2.5.2. Microscopy
Morphology of liposomes was studied under microscope. All
batches of the liposomes prepared were viewed under an Olym-
pus binocular microscope with camera attachment having an
S-Viewer version 1.10.6.2 software to study their shape. The
liposomal dispersion was suitably diluted and put on a glass
slide and viewed with a binocular microscope with magnifica-
tion of 15  100. Scanning electron microscopy (SEM) and
transmission electron microscopy (TEM) of the optimized
liposomal formulation were performed for determining the
surface morphology, size and shape of the formulation and
observing the aggregation property of liposomes.of nanoliposomes of anti schizophrenic agent to the brain through nasal route.
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The particle size and size distribution of liposomes were
determined by Malvern zetasizer based on laser light scatter-
ing principle. A Malvern laser light scattering zetasizer
equipped with an argon laser was utilized for evaluating the
particle size and size distribution. Light scattering was mon-
itored at 90 angle and at 25 C. The mean droplet size
was calculated from intensity, volume and bimodal distribu-
tion assuming spherical particles. The zeta potential is an
indication of the stability of the colloidal systems and indi-
cates charge present in the colloidal systems. Zeta potential
of formulations was determined using Malvern zetasizer.
Samples were placed in clear disposable zeta cells and results
were recorded.
2.6. Ex vivo drug diffusion study
An ex vivo diffusion study was carried out using freshly
derived sheep nasal mucosal epithelium from slaughter house
(Lohan et al., 2015; Aacharya et al., 2015). Mucosal membrane
(0.2 mm thick, 10 mm diameter and 78.5 mm2 area) was fixed
in between receptor and donor compartment of the Franz dif-
fusion cell. 9 sets of cells were used for all the formulations of
liposomal dispersion of QTF. Acceptor compartment was
filled with 10 ml SNF, pH 6.8 and donor compartment was
filled with 1 ml 5% w/v dispersion. All the nine experimental
batches were tested for the ex vivo drug diffusion study and
total amount of the drug content in the dispersion taken for
the study was calculated considering the entrapment efficiency
of individual batch. The temperature in diffusion chamber was
maintained at 37 C using thermostatic water bath. The sample
was withdrawn at time 1, 2, 3, 4, 5 and 6 h and fresh SNF was
added to make the volume. The samples were filtered through
0.45 lm nylon filter membrane and analyzed using spectropho-
tometer for drug content at 242 nm. Results were expressed as
an amount permeated or percent diffusion or ex vivo brain
availability as Eq. (1) as follows:
% Diffusion ¼ Ap 100=At ð1Þ
Ap= amount of QTF in receptor compartment.
At= Initial amount of QTF in donor compartment.
2.7. Optimization
2.7.1. %Entrapment efficiency
The entrapment efficiency was determined by the solvent son-
ication method (Brgles et al., 2008; Tomoko and Fumiyoshi,
2005). Briefly, the vesicles were broken by dissolving 1 g lipo-
somes (equivalent to 167.8 mg QTF) into 10 ml methanol (the-
oretical yield 16.78 mg/ml) and sonicated for 5 min to release
the drug, which was then estimated for the drug content by
diluting up to 100 times (Laouini et al., 2012). The percent
drug entrapped (PDE) was then calculated using the following
Eq. (2).
%Entrapment efficiency ¼ Entrapped drug
 100=Total drug added ð2ÞPlease cite this article in press as: Upadhyay, P. et al., Direct and enhanced delivery
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Studies of the drug release from all the prepared liposomal
batches were directed toward the approaches that are relevant
to the in vivo condition. The in vitro release studies of QTF
from the liposomal dispersion was studied through the dialysis
membrane bag (10 KDa molecular weight, Himedia) in a glass
beaker containing 100 ml of SNF (pH 6.8) at 37 C± 0.5 C
on a temperature controlled magnetic stirrer (Arumugam
et al., 2008; Jung et al., 2009). Dialysis membrane tube previ-
ously soaked overnight in the ethanol was filled with 5 ml of
SNF containing 1 g liposomes. 1 ml volume was withdrawn
at the interval of every 30 min up till 6 h and fresh SNF was
added to make the volume. The samples were diluted with dis-
solution medium and analyzed for drug content.
2.7.3. Regression statistics and analysis of variance (ANOVA)
Application of regression analysis is important to check that
our independent variables have a significant effect on our
response or not. Application of regression also gives us an idea
about the effect of the interaction of both independent vari-
ables on the dependent variable. All data derived from both
the responses were evaluated statistically for their correlation
by regression and ANOVA.
2.7.4. Polynomial equation generation and reduction
The polynomial equations can be used to draw conclusions
after considering the magnitude of coefficient and the mathe-
matical sign it carries (i.e. positive or negative). The equations
may be used to obtain the estimates of response as a small
error of the variance was noticed in three replicates. Reduction
in the equation is based on the significance value, and those
terms are removed, which are insignificant (P> 0.05).
Y1 ¼ b0 þ b1X1 þ b2X2 þ b21X21 þ b22X22 þ b12X1X2 ð3Þ
Eq. (3), Y1 = Encapsulation efficiency,
And,
Y2 ¼ b0 þ b1X1 þ b2X2 þ b21X21 þ b22X22 þ b12X1X2 ð4Þ
Eq. (4), Y2 =%cumulative drug release
b0 = arithmetic mean response of the nine runs,
X1 = Ratio of CH: EPC and X2 = sonication cycles.
2.7.5. Validation of mathematical model
To evaluate the reliability of the developed mathematical
model, all the values of batches for prediction and actual are
compared and residuals are measured. The responses of opti-
mized batch and modified optimized batch are compared.
They are estimated by use of generating a model covering
the entire experimental domain again, residuals versus practi-
cal runs are plotted to check the variation from center line
of each run and predicted value was compared with practical
value and checked for residual. Two checkpoint batches were
prepared, keeping one independent variable constant at one
time and another was slightly fluctuated from standard value.
Practical value was checked for the impact of fluctuated inde-
pendent variables on the dependent variable for which it con-
tributes more.of nanoliposomes of anti schizophrenic agent to the brain through nasal route.
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tuating sonication cycle timing and checked for residual differ-
ence in entrapment efficiency of practical with the predicted
value of the standard one (optimized batch for entrapment effi-
ciency). Similarly, the second checkpoint batch was prepared
by fluctuating molar ratio of CH: EPC and checked for resid-
ual difference in % of drug release of practical with the pre-
dicted value of the standard one (optimized batch for %
drug release).
2.8. Release kinetic studies – release pattern and mechanism
There are several linear and nonlinear kinetic models widely
used to describe release patterns and mechanisms from various
systems and to compare test and reference dissolution profiles.
Linear models include zero order, Higuchi, Hixson-Crowell
and polynomials, whereas the nonlinear models include first
order, Weibull, Korsmeyer-Peppas. The model dependent
methods all rely upon a curve fitting procedure. The method
of Bamba (Bamba et al., 1979) was adopted for deciding the
most appropriate model.
2.9. Animal study
2.9.1. Gamma scintigraphy
All the animal studies were properly designed and performed,
which were reviewed and approved by an institutional animal
ethics committee. For 99mTc labeled solution, 0.4 ml of SNF
pH 6.8 solution was injected into a 10 ml sterile vacuum vial.
A newly prepared solution of SnCl2H2O 0.5 ml was added,
immediately followed by the addition of 0.1 ml of elute con-
taining 1 mCi 99mTc in the form of sodium pertechnetate
(NaTcO4). The mixture was heated for 10 min in a boiling
water bath, and then cooled to room temperature.
For 99mTc labeled liposomal dispersion, above prepared
solution is added in thin film formed in a round flask at the
stage of rehydration instead of SNF pH 6.8. After rehydration
of lipid film by a solution of sodium pertechnetate, sonication
was done to reduce size of lamella. Liposomes were separated
by centrifugation, and redispersed by the addition of SNF pH
6.8. The entrapment efficiency of liposome for the 99mTc was
measured 58.6 ± 7.5% by gamma particle count up to 1000.
After 2 h it was measured 48.1 ± 6.2 indicated that liposomal
99mTc is significantly more stable.
Albino mice weighing 20–25 g were used after overnight
fasting. Two mice were employed in the study. 10 ll liposomal
dispersion containing Technetium99m (equivalent to 250 lCi)
in SNF pH 6.8 (equivalent to 12 mCi/kg body weight) was
administered intranasally to the first mouse while in the second
mouse SNF pH 6.8 solution containing 99mTc was adminis-
tered intranasally of same strength. Dose for mice was calcu-
lated by the same method described for in vivo study
considering 1 mCi/kg dose of human (Hildebrandt et al.,
2008). Gamma photomicrographs were developed at 1000
counts with GE Millennium VG Hawkeye Dual Head Nuclear
Camera (Variable-Geometry Dual Detector Gamma Camera).
2.9.2. In vivo study
Albino mice weighing 20–25 g were used after overnight fast-
ing. Human equivalent dose for mice was calculated by body
surface area (Eq. (6)) as well as weight method (Eq. (7))Please cite this article in press as: Upadhyay, P. et al., Direct and enhanced delivery
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400 mg, so human equivalent dose (HED) is 6.67 mg/kg for
healthy human weighing 60 kg. So,
Animal dose ðmg=kgÞ¼HED ðmg=kgÞ=½Animal km=Human km
¼ 6:6666667=½3=37
¼ 6:6666667=0:0810810810811
¼ 82:222222 ðmg=kgÞ:
ð5Þ
So, dose for mice weighing 20–25 g is 2 mg.
And,
Animal dose ðmg=kgÞ ¼ HED ðmg=kgÞ  wt: factor
¼ 6:67 12 ¼ 80:00 ðmg=kgÞ: ð6Þ
So, dose for mice weighing 20–25 g is 2 mg.
Two groups of mice were employed in the study and all the
readings were taken in triplicate (n= 3) for each time point.
10 ll QTF dispersion containing 2 mg QTF in SNF pH 6.8
was administered intranasally to the first group while in the
second group QTF 10 ll liposomes containing 2 mg QTF
was administered intranasally. For this study, mice were tied
up in supine condition and nasal administration was done by
micropipette. Mice were sacrificed after every 1 h interval of
administration by stunning and blood was collected from car-
otid artery after decapitation and intact brains were excised
from the skull and homogenized immediately at 5000 rpm
for 10 min under chilled condition. Brain homogenate was
made acidic by adding 1 ml of phosphate buffer (pH 3) and
the drug was extracted twice times by adding mixture of
0.6 ml chloroform and 0.4 ml of methanol. The organic layer
was separated after centrifugation at 5000 RPM for 10 min
at 4 C and evaporated under vacuum. The residue was resus-
pended in 1.6 ml acetonitrile and 0.4 ml HPLC grade methanol
and then analyzed by HPLC method.
2.9.3. Nasal ciliotoxicity study
After diffusion study, nasal mucosa is unmounted from diffu-
sion cell and stained with Safranin and eosin, and then analyzed
under an Olympus microscope and compared with untreated
nasal mucosal layer to check for any conformational changes.
3. Results and discussion
3.1. Analytical method
The Uv overlay absorption spectra were taken and the stan-
dard calibration curve was generated for the entire range from
5 to 25 lg/ml. Linearity was observed between 5 and 25 lg/ml
at 242 nm in SNF pH 6.8. Equation Derived from Standard
calibration curve is y= 0.0079x  0.005 having value
R2 = 0.9978. Similarly, in HPLC method standard retention
peak of the drug was observed at 5 min with peak area
1,195,711. Both the methods are indicated as shown in Fig. 1.
3.2. Characterization and evaluation
3.2.1. Drug - excipient compatibility study
FTIR spectra of alone QTF show its characteristic functional
group peaks shown in Fig. 2 and QTF with the excipientsof nanoliposomes of anti schizophrenic agent to the brain through nasal route.
Figure 1 Analytical determination of QTF. A. Uv overlay absorption spectra of different dilutions of QTF; B. HPLC chromatogram of
QTF.
Figure 2 FTIR of. A. QTF pure; B. Mixture of QTF with excipient; C. Cholesterol; D. EPC.
6 P. Upadhyay et al.shows almost same peak as the pure drug. Comparison of the
peaks of the functional group obtained from QTF alone and
QTF with excipients was done. In QTF with excipients spectra
the fingerprint region and 4000–2000 cm1 region show the
peaks are identical to QTF functional groups as shown in
Table 2. So, QTF is compatible with the excipients used in
the formulation and no functional group loss or interaction
of QTF with excipients was observed.Please cite this article in press as: Upadhyay, P. et al., Direct and enhanced delivery
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It can be stipulated from the photomicrograph that circular
vesicles of phospholipid were formed. Scanning electron
microscopy of the optimized liposomal formulation showed
the intact, regular surface of completely dispersed liposomal
spheres as shown in Fig. 3. From transmission electron
microscopy, thick and rigid liposomal lamella has been
identified.of nanoliposomes of anti schizophrenic agent to the brain through nasal route.
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Average Particle size measured is 139.6 nm having intensity
100% and width 35.26 nm shown in Fig. 4. That means all
the particles are within the range of 121.97 nm to 157.23 nm
having a maximum accumulation at 139.6 nm. Here the zeta
potential is 32.1 mV having intensity 100% and width
9.26 mV. That means all the particles are within the range of
27.47 mV to 36.73 mV having a maximum accumulation at
32.1 mV which indicates the system is moderately stable
(Michel and Suzuki, 1985).
3.3. Ex vivo drug diffusion study
The drug diffusion was maximum of 59.02 ± 1.22 for formu-
lation batch F7 containing 1:3 M ratio of cholesterol: EPC.
Increasing the EPC content resulted in an increased drug
release due to its bipolar nature which facilitates drug diffusion
across biological membrane (Chandaroy et al., 2002). In Fig. 5
and Table 3, batch F7 also had a maximum release, which can
be correlated with diffusion across a membrane by a concen-
tration gradient.Table 2 FTIR Analysis of drug and mixture.
Functional group Standard frequency (cm1) Observed fre
CAH-Stretch mode 2962–2853 2920.23
C‚O-Stretch mode 1725–1705 1737.86
NAH-Stretch mode 1575–1600 1541.12
C‚C-Stretch mode 1600–1690 1670.35
CAN-Stretch mode 1250–1340 1375.26
CAC-Stretch mode 1450–1600 1438.9
Figure 3 Microscopic images of liposomal formulation. A. Ligh
1 cm = 100 nm); C. TEM (Scale: 1 cm = 100 nm).
Figure 4 Zetasizer graph of optimized batch F7. A. Average par
determination.
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3.4.1. Entrapment efficiency
The maximum entrapment efficiency is observed in thrice
time’s ratio of EPC to cholesterol (Batch F4) among all other
batches as shown in Fig. 6. This is due to the requirement of
the abundant amount of EPC to make the lamellar structure
of liposomes and cholesterol is supplement of lamella and
increases stability as flexibility buffer. At an appropriate ratio
of CH and EPC there is formation of rigid bilayers, which
increases stability and entrapment efficiency of liposomes.
Decrease in entrapment efficiency with increasing CH:EPC
ratio at higher level is also observed, which is due to decrease
in CH below certain concentration can disrupt the regular lin-
ear structure of liposomal membrane formed by EPC as a
cause of instability. This may result in rupture of bilayers,
which results in decreased entrapment efficiency.
Moreover, sonication cycles were applied to decrease the
size of the liposomes formed at the last step of the formulation,
which can result into the disruption of certain vesicles and
hence decrease entrapment efficiency. From Table 4 it can bequency of QTF (cm1) Observed frequency of mixture (cm1)
2954.55
1735.5
1551.46
1676.15
1377.17
1465.9
t microscope with magnification of 15  100; B. SEM (Scale:
ticle size and size distribution measurement; B. Zeta potential
of nanoliposomes of anti schizophrenic agent to the brain through nasal route.
Figure 5 %Diffusion of liposomal dispersion (batches F1–F9)
across sheep nasal mucosa with respect to time (n= 3).
Figure 6 %Entrapment efficiency of all the batches (F1–F9)
(n= 3).
8 P. Upadhyay et al.stated that entrapment efficiency is maximum with least soni-
cation cycles. Maximum entrapment efficiency was obtained
with 1:2 (CH:EPC) molar ratio and 2 cycles of the sonication,
so batch F4 is giving maximum entrapment efficiency of 78.66
± 3.42.
3.4.1.1. Full model equation.
Y1 ¼ 65:33222þ 1:873333X1  16:175X2  3:09833X21
 5:95333X22  0:6225X1X2 ð7Þ
The full model was evolved as in Eq. (8) and refined by
excluding the terms for which the level of significance was
greater than 0.05. The significant levels P of the coefficients
b0, b1, b2, b12, b11 and b22 were found to be 0.0000164,
0.075085, 0.000177, 0.083318, 0.016121 and 0.519831 respec-
tively. So, b1, b12 and b11 have significance greater than 0.05,
so they were omitted from the full model to generate a reduced
model equation. The coefficients b0, b2, & b22 were found to be
significant as P< 0.05; hence, they were retained in the
reduced model.
3.4.1.2. Reduced model equation.
Y1 ¼ 65:33222 16:175X2  5:95333X22 ð8Þ
So, from Eq. (9) of the reduced model, it can be qualita-
tively concluded that X2 (16.175) had the negative effect on
the response of Y1, which indicated that as the number of son-
ication cycles increases, %EE decreases. The negative value of
X2
2 with significance above 99.95% indicates the number of
sonication cycles has an inverse effect on %EE. Here, as the
ratio of cholesterol to EPC increases, there is a slight increaseTable 3 Ex vivo drug diffusion study of all batches (F1–F9) (n= 3
Time (h) F1 F2 F3 F4 F5
0 0 0 0 0 0
1 1.03 ± 0.36 0.80 ± 0.31 0.91 ± 0.39 3.07 ± 0.27 2.0
2 3.38 ± 0.37 2.99 ± 0.23 2.86 ± 0.64 6.41 ± 0.45 4.5
3 6.11 ± 0.78 6.40 ± 0.44 5.56 ± 0.58 11.55 ± 0.70 8.6
4 8.03 ± 1.09 9.48 ± 0.69 8.19 ± 1.42 15.74 ± 0.70 12.
5 13.46 ± 1.49 15.28 ± 0.13 13.61 ± 1.25 22.10 ± 0.83 18.
6 20.82 ± 0.79 22.84 ± 0.78 19.76 ± 1.06 29.34 ± 0.79 26.
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very close to significant value of 0.07. Moreover, its square is
also very close to significant value. So, the X1 has a minor pos-
itive effect on %EE (Y1) means ratio itself as an X1 contribute
at smaller consent, and also at a very high level it decreases
response Y1. Higher values of correlation coefficient for %
EE indicate a good fit.
3.4.2. In vitro drug release study
The drug release was maximum for formulation containing
1:3 M ratio of cholesterol: EPC. Increasing the EPC content
resulted in a more drug release due to its bipolar nature which
facilitates drug diffusion across lipid lamella as indicated in
Fig. 7 and Table 5. Maximum drug release 99.920 ± 1.88
was observed with batch F7 at 6 h.
3.4.2.1. Full model equation.
Y2 ¼ 90:74633þ 5:983833X1  3:26283X2 þ 0:1285X21
þ 0:2985X22 þ 0:75075X1X2 ð9Þ
The full model was evolved and refined by excluding the
terms for which the level of significance was greater than
0.05 as per Eq. (10). The significant levels P of the coefficients
b0, b1, b2, b12, b11 and b22 were found to be 0.000000602,
0.000342, 0.002057, 0.832852, 0.630144 and 0.153524 respec-
tively, so b1
2, b2
2 and b12 have significance greater than 0.05,
so they were omitted from the full model to generate a reduced
model equation. The coefficients b0, b1 and b2 were found to be
significant at P< 0.05; hence, they were retained in the
reduced model.).
F6 F7 F8 F9
0 0 0 0
9 ± 0.09 1.75 ± 0.08 2.71 ± 0.49 2.36 ± 0.36 2.02 ± 0.33
9 ± 0.60 3.83 ± 0.30 6.71 ± 0.66 4.36 ± 0.60 4.99 ± 0.39
8 ± 0.91 7.25 ± 0.29 12.79 ± 1.29 7.75 ± 0.94 10.38 ± 0.60
59 ± 0.86 10.51 ± 0.61 17.84 ± 1.17 12.78 ± 1.31 13.70 ± 0.84
97 ± 0.82 16.78 ± 0.74 24.43 ± 0.84 18.20 ± 1.49 20.21 ± 1.01
38 ± 0.74 24.34 ± 0.88 32.33 ± 1.53 26.13 ± 1.14 26.62 ± 0.89
of nanoliposomes of anti schizophrenic agent to the brain through nasal route.
Table 4 %EE of all batches (F1-F9) (n= 3).
Batch Absorbance Conc. (lg/ml) Dilution factor Conc. (mg/ml) %EE
F1 0.9101 ± 0.0214 115.84 ± 3.34 100 11.584 ± 0.334 69.03 ± 1.99
F2 0.7831 ± 0.0188 99.76 ± 3.01 100 9.976 ± 0.301 59.45 ± 1.79
F3 0.4718 ± 0.0219 60.35 ± 3.40 100 6.35 ± 0.340 37.84 ± 2.03
F4 1.0381 ± 0.0403 132.04 ± 5.73 100 13.2 ± 0.573 78.66 ± 3.42
F5 0.8522 ± 0.0191 108.5 ± 3.05 100 10.85 ± 0.305 64.66 ± 1.82
F6 0.6111 ± 0.022 77.99 ± 3.42 100 7.799 ± 0.342 46.48 ± 2.04
F7 0.9978 ± 0.045 126.94 ± 6.33 100 12.69 ± 0.633 75.63 ± 3.77
F8 0.7901 ± 0.026 100.65 ± 3.92 100 10.065 ± 0.392 59.98 ± 2.34
F9 0.5511 ± 0.0118 70.39 ± 2.13 100 7.039 ± 0.213 41.95 ± 1.27
Figure 7 %Cumulative drug release of QTF with respect to time
(n= 3).
Nanoliposomal Quetiapine Fumarate delivery to the brain through nasal route 93.4.2.2. Reduced model equation.
Y2 ¼ 90:74633þ 5:983833X1  3:26283X2 ð10Þ
So, from Eq. (10) of the reduced model, it can be qualita-
tively concluded that X1 (5.983833) had the positive effect on
the response of Y2, which indicated that as the ratio of EPC
to cholesterol increases, %CDR greatly increases. This is due
to a surfactant property of EPC, it leads into increased diffu-
sion of QTF across the cholesterol lipidic layer. Oppositely,
as the number of sonication cycle decreases the %EE, also
results in declining of %CDR.Table 5 In vitro drug release study of all batches (F1–F9) (n= 3).
Time (h) Cumulative % drug release (Q24)
F1 F2 F3 F4 F5
0 0 0 0 0 0
0.5 2.57 ± 1.6 2.0 ± 2.8 2.28 ± 2.8 7.67 ± 1.1 5.23
1 6.75 ± 2.7 5.98 ± 1.5 5.72 ± 1.5 12.82 ± 2.4 9.18
1.5 9.40 ± 1.8 9.85 ± 1.9 8.56 ± 1.2 17.77 ± 2.9 13.36
2 11.47 ± 2.6 13.54 ± 3.6 11.7 ± 3.6 22.482 ± 3.7 17.98
2.5 17.94 ± 4.6 20.37 ± 2.4 18.14 ± 2.9 29.464 ± 4.1 25.29
3 26.03 ± 2.4 28.55 ± 3.0 24.7 ± 1.8 36.68 ± 2.6 32.97
3.5 34.07 ± 3.5 36.72 ± 2.7 32.75 ± 2.5 43.05 ± 1.6 39.39
4 40.40 ± 5.1 44.05 ± 1.8 39.98 ± 3.2 52.26 ± 3.3 46.07
4.5 54.17 ± 4.3 57.39 ± 2.2 54.17 ± 2.1 64.49 ± 2.5 58.78
5 68.42 ± 2.9 69.22 ± 1.0 62.96 ± 1.5 78.53 ± 1.2 72.75
5.5 81.33 ± 1.5 81.15 ± 1.8 75 ± 1.3 89.67 ± 1.9 85.11
6 88.81 ± 2.070 85.35 ± 2.42 81.11 ± 1.76 94.450 ± 2.22 91.11
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The first checkpoint batch was prepared with CH: EPC molar
ratio 1:2 and 2 sonication cycles by 80% amp of 2.5 min dura-
tion and checked for residual with F4 batch for entrapment
efficiency. Similarly, the second checkpoint batch was pre-
pared with CH: EPC molar ratio 1:2.5 and 2 sonication cycles
by 80% amp of 2 min duration and checked for residual with
F7 batch for % drug release.
The predicted value of %EE for checkpoint batch was
78.66 ± 3.42 of F4, and actual reading by three consecutive
determinations was 73.03 ± 1.52, so residual was derived
5.63. Similarly, predicted value of %CDR for checkpoint
batch was 99.66925 of F7, and actual reading by three consec-
utive determinations was 96.90 ± 1.88, so residual was derived
2.76925. It can be speculated from Table 6 that there is no sig-
nificant difference in actual and predicted value of %EE and
%CDR. So, we can conclude that our reduced model equation
has good predictive power.
3.5. Release kinetic studies – release pattern and mechanism
Maximum goodness of fit value R2 is observed 0.9941 for opti-
mized batch F7 for Hopfenberg and Korsmeyer-Peppas than
that of any other dissolution model. The Hopfenberg model
suggests that drug release from surface eroding polymers so
long as the surface area remains constant during the degrada-
tion process. Further that can be validated by performing
Korsmeyer-Peppas modeling and finding value of releaseF6 F7 F8 F9
0 0 0 0
± 1.3 4.37 ± 1.2 6.131 ± 2.6 5.89 ± 2.9 5.05 ± 1.4
± 5.2 7.66 ± 1.9 11.047 ± 1.9 8.71 ± 1.2 9.972 ± 2.9
± 1.6 11.16 ± 4.2 16.501 ± 3.6 11.93 ± 1.5 15.97 ± 1.7
± 2.4 15.01 ± 3.1 20.78 ± 1.4 18.25 ± 2.3 19.57 ± 2.3
± 3.6 22.37 ± 2.5 26.63 ± 2.1 24.27 ± 1.6 26.94 ± 3.1
± 1.9 30.42 ± 1.8 32.35 ± 1.8 32.66 ± 1.9 33.27 ± 1.5
± 2.7 36.50 ± 2.8 39.29 ± 3.8 38.71 ± 1.1 40.43 ± 3.5
± 2.2 42.41 ± 1.4 47.42 ± 3.2 46.17 ± 2.6 47.83 ± 2.2
± 3.8 55.13 ± 3.8 63.07 ± 2.7 59.08 ± 2.3 66.85 ± 2.8
± 2.4 70.59 ± 2.9 77.45 ± 2.0 75.89 ± 1.3 78.49 ± 1.9
± 1.7 81.75 ± 1.1 92.48 ± 1.3 90.36 ± 1.5 90.14 ± 2.1
6 ± 1.00 87.27 ± 2.12 99.920 ± 1.88 96.030 ± 1.11 95.223 ± 2.01
of nanoliposomes of anti schizophrenic agent to the brain through nasal route.
Table 6 Regression analysis and ANOVA for Y1 and Y2.
Regression statistics for Y1
Multiple R 0.997395
R Square 0.994798
Adjusted R square 0.986127
Standard error 1.712563
Observations 9
Anova
DF SS MS F Significance F
Regression 5 1682.474 336.4947 114.7321 0.001268
Residual 3 8.798619 2.932873
Total 8 1691.272
Results of checkpoint batch
Predicted Actual Residual
74.95139 73.03 ± 1.52 1.92139
Regression statistics for Y2
Multiple R 0.996687
R Square 0.993386
Adjusted R square 0.982362
Standard error 0.789968
Observations 9
ANOVA
DF SS MS F Significance F
Regression 5 281.1798 56.23596 90.11458 0.001816
Residual 3 1.872148 0.624049
Total 8 283.0519
Results of checkpoint batch
Batch Predicted Actual Residual
1 78.66 73.03 ± 1.52 5.63
2 99.66925 96.90 ± 1.88 2.76925
Figure 8 Gamma scintigraphy results after nasal administration of. A
in mice (Posterior (B) and anterior (b)).
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mechanism of the drug release follows supercase Case II.
Supercase II mechanism generally refers to erosion of poly-
meric chain and anomalous transport (non-Fickian) refers to
a combination of both diffusion and erosion controlled drug
release and independent of a concentration gradient.
Generally release from liposomal lamella of lipophilic drugs
follows zero order and Fickian mechanism of transport that
release by concentration gradient in an isotonic solution. Sim-
ulated nasal fluid is slightly hypotonic to body fluids which
results in its swelling and rupturing of liposomal sac. More-
over, at the body temperature of 37 C, EPC get melted down
(Tm of EPC is 20 C); hence, liposomes get eroded. The drug
entrapped in the layers of the lamella, is released by the diffu-
sion mechanism. As the lamellar backbone of the cholesterol
and lecithin degrades, the drug from the core of the liposomes
is released by breakdown/ erosion mechanism.
3.6. Animal study
3.6.1. Gamma scintigraphy
The scintigraphy pictures in mice after intranasal administra-
tions are demonstrated in Fig. 8. This obviously exhibits signif-
icant radioactivity aggregation in the brain after intranasal
administration for a desired period and these results are in
great concurrence with the past discoveries (Patil et al.,
2010). Results of gamma scintigraphy study revealed that lipo-
somal dispersion shows more accumulated TC99m into the
brain to compare to solution of TC99m. Elevated TC99m accu-
mulation into the brain by liposomes confirms its efficiency of
targeted delivery. Moderate amount of TC99m into the lungs
and respiratory tract through nasal route administration is
observed as breathing in mice during nasal administration
drags the dispersion into those tissues. From Study, it is clearly
stated that, accumulation of 99mTc is more in the brain of
intranasally given liposomes than that of the simple solution.. QTF liposome (Posterior (A) and anterior (a)); B. QTF solution
of nanoliposomes of anti schizophrenic agent to the brain through nasal route.
Figure 9 Amount of QTF in brain homogenate (ng/ml)
containing liposome and simple dispersion (n= 3).
Table 7 QTF amount (ng/ml) into the brain homogenate
after nasal administration (n= 3).
Time (hr) QTF amount (ng/ml) into the brain
QTF dispersion QTF liposomes
1 157.3333 ± 55.89574 85 ± 33.6006
2 191 ± 48.77499 177.6667 ± 39.8288
3 225.3333 ± 31.56475 255 ± 40.15
4 92.66667 ± 8.621678 221.6667 ± 8.144528
5 49.33333 ± 8.504901 116.3333 ± 18.037
6 21.66667 ± 8.736895 46 ± 12.16553
Nanoliposomal Quetiapine Fumarate delivery to the brain through nasal route 113.6.2. In vivo study
The brain:plasma amount for different formulations adminis-
tered indicated that the brain:plasma ratio for QTF liposomes
administered by intranasal route was significantly higher
(p< 0.05, n= 3) in comparison with QTF dispersion as indi-
cated in Table 7. Initially, the amount obtained by liposome
was less than that obtained by the simple dispersion. But after
that, in the second phase, the amount obtained for both disper-
sions was almost similar. And at the last, liposomes exceeded
the availability of QTF in the mouse brain. QTF diffusion
occurred at a constant rate of the dispersion, while for lipo-
some, QTF diffusion gradually increased. That’s why, though
QTF diffusion was higher in dispersion in the first phase, at
last phase diffusion by liposome was higher. These results
support the existence of an alternative brain entry pathwayFigure 10 Photomicrographs of sheep nasal mucosa. A. Control; B
QTF; C. Nasal mucosa treated with IPA.
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cated by rapid drug uptake obtained after intranasal adminis-
tration of QTF liposome in comparison with QTF dispersion
administered Fig. 9.
3.6.3. Nasal ciliotoxicity study
Nasal ciliotoxicity studies (Fig. 10) revealed that nasal mucosa
treated with SNF pH 6.8 (negative control) showed intact
epithelium layer without any necrosis while nasal mucosa trea-
ted with isopropyl alcohol (positive control mucociliary toxic
agent) showed complete destruction of epithelium layer and
necrosis and even the deeper tissue parts were also destroyed.
QTF liposomes prepared in our studies did not exhibit any
toxicity, as no change could be noticed in the gross morphol-
ogy and histology of the nasal mucosa.
4. Conclusion
Liposomal formulation containing QTF was successfully
formed using cholesterol and EPC using 32 factorial design.
The maximum entrapment efficiency was observed in batch
F4 which was prepared with 1:2 CH:EPC ratio and 2 cycles
of sonication. There was an increase in entrapment efficiency
to decrease with sonication cycles and increase in release with
an increase in EPC ratio. The batch F7 was optimized based
on dissolution study and evaluated for diffusion study. Results
reveal that liposome had higher diffusivity than dispersion. In
vivo and scintigraphy study proved that the formulation has
better potential to deliver drugs to the brain than by the simple
dispersion and solution. Higher brain uptake and distribution
of QTF from liposomes for intranasal administration com-
pared to simple dispersion indicated that the developed formu-
lation can be a good platform for administration of drugs
targeting the brain.
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